Limited Supply of RSV Anti-Body Drug

Translate to Spanish or other 102 languages!

It is important to note that the long-acting RSV monoclonal antibody is one of two new tools we have this season to protect babies from severe RSV illness. Image for illustration purposes
It is important to note that the long-acting RSV monoclonal antibody is one of two new tools we have this season to protect babies from severe RSV illness. Image for illustration purposes

Mega Doctor News

- Advertisement -

By Texas Tech University Health Sciences Center El Paso

Newswise — Glenn J. Fennelly, MD, MPH, professor, and chair, Department of Pediatrics, Texas Tech Health El Paso can speak on the shortage of the antibody for RSV in children. 

How can parents work around the shortage? 

- Advertisement -

It is important to note that the long-acting RSV monoclonal antibody is one of two new tools we have this season to protect babies from severe RSV illness.

Pregnant women have the opportunity to receive a new RSVpreF vaccine manufactured by Pfizer that was recently approved by the FDA. Immunization of the mother during weeks 32 through 36 of pregnancy with this vaccine reduces the risk of RSV hospitalization for their babies by 57 percent in the first six months after birth if given more than two weeks before delivery. 

How can parents take care of their children?

Strict handwashing before holding or feeding your infant, as well as avoiding close contact with other children or adults who have symptoms of respiratory infections are other ways to avoid RSV and other respiratory illnesses.

- Advertisement -

Vaccination against influenza is recommended for all infants 6 months or older, and should be considered for all children to help avoid complications from influenza infection that may be severe.

For grandparents or other close family members age 60 or higher, vaccination of these adults with one of two alternative RSV vaccines that have recently been approved by the FDA may also help to prevent transmission to infants.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Practical Health Tips to Navigate Cold and Flu Season Safely

With cold and flu season in full swing, experts say there are some simple steps you can take to protect yourself and those around you.

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.

DHR Health to Host 13th Annual Circle of Care Caregivers Conference

DHR Health Rehabilitation Hospital will host its 13th Annual Circle of Care Caregivers Conference on Saturday, November 7, 2026, at the Edinburg Conference Center at Renaissance, offering educational presentations and resources for individuals caring for family members and loved ones.
- Advertisement -